Group 1: OTC Strategy and Performance - The company has adjusted its OTC strategy by merging the OTC sales department with the OTC marketing department to form the OTC division, enhancing overall marketing and sales efficiency [1] - A new large packaging product was launched, and strategic partnerships with leading chains were formed, contributing to significant sales growth in the outpatient channel in the first half of the year [1] Group 2: Future Growth Potential of Wuling Capsule - The company aims to develop Wuling Capsule into a product with a market scale exceeding 2 billion, leveraging the high sleep disturbance rate of 48.5% among the population aged 18 and above [2] - Currently, OTC sales revenue from Wuling Capsule accounts for approximately 10%, with plans to increase this to over 20% through enhanced C-end strategies [2] - Wuling Capsule is currently available in about 15,000 hospitals, with significant room for expansion given the total number of medical institutions in China exceeds one million [2] Group 3: Investment in Lingyi Biotech - Lingyi Biotech focuses on innovative drug development for single-gene hereditary diseases, with a recent investment of 20 million yuan made by the company in April 2025 [3] - The collaboration is expected to enhance the company's capabilities in the neurological field, particularly through the LY-N001 pipeline targeting Parkinson's disease [3] - Future investments in Lingyi Biotech will depend on the progress and breakthroughs of the LY-N001 pipeline [3]

Core Viewpoint - Zhaoli Pharmaceutical announced the election of Shen Yuehong as the employee representative director of the company's eighth board of directors during a recent employee representative meeting [2] Group 1 - The employee representative meeting was held recently [2] - Shen Yuehong was elected as the employee representative director [2]

Group 1 - The core point of the article is that Zhaoli Pharmaceutical announced the approval of several proposals, including the amendment of the company's articles of association, during its first extraordinary general meeting of shareholders in 2025 [2] Group 2 - The announcement was made on the evening of September 5, indicating the company's ongoing governance and regulatory compliance efforts [2] - The approval of the proposals reflects the company's strategic direction and potential future initiatives [2]

Group 1 - The company, Zhaoli Pharmaceutical, announced the approval of the audit committee members and the convener during the eighth temporary meeting of the eighth board of directors [2] - The company also approved the supplementary election of members for the strategic and ESG committee of the eighth board of directors [2]

证券代码：300181 证券简称：佐力药业 公告编号：2025-057 浙江佐力药业股份有限公司 关于董事辞任暨选举职工代表董事及补选董事 会战略与ESG委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事辞职情况 浙江佐力药业股份有限公司（以下简称"公司"）董事会于近日收到非独立 董事沈月红女士递交的书面辞职报告。因公司治理结构调整，沈月红女士辞去公 司第八届董事会非独立董事职务及第八届董事会战略与ESG委员会委员职务。根 据《公司法》及《公司章程》等有关规定，沈月红女士的辞任不会导致公司董事 会人数低于法定最低人数，其辞职报告自送达公司董事会之日起生效，沈月红女 士辞任后将继续在公司担任其他职务。 截至本公告披露日，沈月红女士未直接或间接持有公司股份，不存在应当履 行而未履行的承诺事项。沈月红女士辞去公司董事及战略与ESG委员会委员职务 后，将继续遵守《公司法》《上市公司董事和高级管理人员所持本公司股份及其 变动管理规则》《深圳证券交易所创业板股票上市规则》等法律法规及规范性文 件的相关规定。 二、选举职工代表董事情况 根据《公司法》 ...

证券代码：300181 证券简称：佐力药业 公告编号：2025-055 浙江佐力药业股份有限公司 2025年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 特别提示： 1、本次股东大会未出现否决议案的情形； 2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议召开和出席情况 （一）会议召开情况 1、会议召集人：浙江佐力药业股份有限公司（以下简称"公司"或"本公司"） 董事会 2、会议召开时间：（1）现场会议召开时间：2025年9月5日（星期五）下午 14:00（2）网络投票时间：通过深圳证券交易所（以下简称"深交所"）交易系统 进行网络投票的具体时间为：2025年9月5日（星期五）上午9:15—9:25， 9:30—11:30 和下午13:00—15:00；通过深交所互联网投票系统投票的具体时间 为：2025年9月5日（星期五）上午9:15至下午15:00期间的任意时间。 3、会议召开地点：浙江省德清县阜溪街道志远北路388号，浙江佐力药业股 份有限公司会议室。 4、会议召开方式：采取现场投票和网络投票相结合的方式。 5、 ...

上海东方华银律师事务所 关于浙江佐力药业股份有限公司 2025 年第一次临时股东大会的法律意见书 本所律师仅就本法律意见书出具日以前所发生的事实以及本所律师对有关 法律法规的理解发表法律意见。 本法律意见书仅供公司为本次股东大会之目的使用，不得用于其他任何目的。 本所同意本法律意见书作为公司本次股东大会公告材料，随其他资料一起向社会 公众披露，并依法承担相关的法律责任。 本所律师根据法律法规和《公司章程》的要求，按照律师行业公认的业务标 准、道德规范和勤勉尽责精神，现出具法律意见如下： 一、本次股东大会召集、召开的程序 致：浙江佐力药业股份有限公司 上海东方华银律师事务所（以下简称"本所"）接受浙江佐力药业股份有限 公司（以下简称"贵司"或"公司"）委托，就贵司召开 2025 年第一次临时股东 大会的有关事宜，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上 市公司股东股东会规则》（以下简称"《股东会规则》"）等法律、法规和其他规范 性文件以及《浙江佐力药业股份有限公司章程》（以下简称"《公司章程》"）的有 关规定，出具本法律意见书。 为出具本法律意见书，本所律师审查了公司提供的本次股东大会的相关 ...

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没 有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 浙江佐力药业股份有限公司 第八届董事会第八次（临时）会议决议公告 证券代码：300181 证券简称：佐力药业 公告编号：2025-056 根据《中华人民共和国公司法》《上市公司章程指引》等相关法律法规、规 范性文件的规定，公司对第八届董事会审计委员会成员和召集人进行确认，公司 第八届董事会审计委员会仍由朱建先生（独立董事）、王萍先生（独立董事）、 郑学根先生组成，其中朱建先生为审计委员会召集人且为会计专业人士。任期自 本次董事会审议通过之日起至第八届董事会任期届满之日止。 表决结果：同意 9 票，反对 0 票，弃权 0 票，获得通过。 2、审议通过《关于补选第八届董事会战略与 ESG 委员会委员的议案》 因公司治理结构调整，沈月红女士辞去公司第八届董事会非独立董事、战略 与 ESG 委员会委员职务。同时，公司于近日召开职工代表大会，经全体与会职 工代表表决，选举沈月红女士为公司第八届董事会职工代表董事。 公司董事会重新选举沈月红女士为公司第八届董事会战略与 ESG 委员会委 员，任期自本次 ...

Core Viewpoint - The company is focusing on the research and development of innovative traditional Chinese medicine, particularly the Wuling series products [1] Group 1 - The company is actively implementing a strategic layout of "initiating a batch, conducting clinical trials for a batch, and launching a batch" [1] - Currently, the company has innovative drugs under research, including Lingxiang tablets, which are undergoing Phase II clinical trials [1] - There are three other innovative traditional Chinese medicines from the Wuling series that are in preclinical toxicology and pharmaceutical research [1]

Group 1 - The core business of the company includes various products such as the Wuling series (Wuling capsules, Lingze tablets, Linglianhua granules), the Bailing series (Bailing tablets, Bailing capsules), traditional Chinese medicine pieces, and traditional Chinese medicine formula granules, as well as Pugakabofe calcium tablets [2] - The Wuling series is a unique product line, and the company aims to develop new products based on Wuling mushroom powder according to famous doctors' prescriptions, with a goal of expanding the Wuling series into a family of 10 products to create a stronger product moat [2]